CBRN investments support advanced research & development and procurement of medical countermeasures to address national security threats.
BARDA is the lead office within HHS for the advanced research & development (AR&D) as well as procurement of medical countermeasures (MCMs) to protect the American civilian population from CBRN threats. Ultimately, these MCMs are used to help the Nation prepare for, respond to, and recover from public health emergencies arising from naturally occurring and intentionally engineered threats. CBRN uses its AR&D authorities to help innovators develop promising candidate MCMs from preclinical development to clinical trials and manufacturing scale-up to FDA approval. CBRN leverages its Project BioShield (PBS) authorities to procure approved or approvable MCMs to save lives and protect Americans from 21st century health security threats.
Make Available at Least One Countermeasure for all CBRN Material Threats
The goal of AR&D funding is to build a sustainable MCM pipeline to prevent or treat illnesses and injuries caused by CBRN threats. AR&D funds support innovative products through all phases of the development pipeline, from discovery and preclinical research, to clinical trials needed to prove safety and efficacy, and manufacturing and regulatory approval needed to bring a product to market. CBRN also uses AR&D funding to develop and utilize preclinical models to study the illnesses and injuries caused by CBRN threats and the MCMs to treat those illnesses and injuries.BARDA is investing in an array of medical countermeasures to treat or prevent illnesses and injuries caused by CBRN threats under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003).
BARDA uses Project BioShield funding to support late-stage development, including post-marketing requirements and Phase IV clinical trials, and procurement of critical medical countermeasures, including vaccines and therapeutics, to prevent and treat CBRN threats. These MCMs are made available when a public health emergency, such as an anthrax attack or a nuclear detonation, occurs.Check back soon for links to Requests for Proposals (RFP) for new efforts to be supported by Project BioShield funds.
Learn how DRIVe and CBRN are collaborating to form new partnerships under the new ReDIRECT program to repurpose drugs approved for other indications to treat injuries caused by chemical threats.
CBRN has a proven track record of developing life-saving medical countermeasures. We will continue to work with partners old and new to treat or prevent the medical consequences that result from CBRN threats.
Threat Area Filters
Impact Area Filters